Denovicon Therapeutics has been renewed for a three-year membership in the 3DEXPERIENCE Lab accelerator, the global innovation program of Dassault Systèmes. Denovicon remains the only biotechnology company in the accelerator’s portfolio, underscoring the program’s confidence in our AI-driven approach to small-molecule drug discovery.
Since our initial acceptance in October 2024, we have deepened our collaboration with Dassault Systèmes and its BIOVIA life sciences division, working together across multiple projects at the intersection of computational chemistry and machine learning.
We look forward to continuing this work and to pushing the boundaries of what’s possible in AI-enabled drug discovery alongside the 3DEXPERIENCE Lab community.